AzTrials
AzTrials

Alzheimer DiseaseNCT06151808

Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects

A study testing XTR006 in people with Alzheimer Disease, run by Sinotau Pharmaceutical Group at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is an investigator-initiated clinical (IIT)study.The main purpose of this study was to evaluate the diagnostic efficacy of XTR006 PET qualitative reading and quantitative analysis in detecting mild cognitive impairment（MCI）due to AD and mild to moderate AD based on clinical diagnosis, and to establish XTR006 PET… Read more about this study

Who is it for?
Ages 55 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Alzheimer Disease
What is being tested?
XTR006
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
42 participants
Where
1 siteChina
Study dates
1 Sep 2022to 10 Jan 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 1. Inclusion criteria for non-cognitively impaired subjects
  • Male or female aged between 55 to 85 years old (including 50 and 85 years old);
  • Clinical dementia score (CDR) of 0;
  • the Mini-Mental State Examination Scale (MMSE score) of ≥28;
  • Aβ PET imaging is negative;
  • Able to cooperate with the tests required for research including neuropsychological tests (cognitive ability, language ability, visual and auditory acuity can meet the requirements of the test);
Show all 29Show fewer
  • The researcher judges that the subjects are in good health, and there is no abnormal or abnormality in the comprehensive physical examination, vital sign examination and laboratory examination, but they can participate in this bridging clinical trial according to the judgment of the clinician;
  • For women of potential fertility (not yet or within 2 years of menopause), effective contraceptive measures must be used during the study period and within 6 months after the end of the study (effective contraceptive measures refer to sterilization, intrauterine hormonal devices, contraception condoms, contraceptives/dose, abstinence or partner removal of the vas deferens, etc.); male subjects should agree to use contraceptives during the study period and within 6 months after the end of the study period;
  • Able to sign the informed consent form.
  • 2. Inclusion criteria for MCI due to AD
  • Male or female aged between 55-85 years old (including 50 and 85 years old);
  • Diagnosed as MCI due to AD according to NIA-AA standard in 2011;
  • Have symptoms of subjective memory loss and maintain independent ability of daily life;
  • MMSE score≤27;
  • CDR score=0.5;
  • Aβ PET imaging is positive;
  • Able to cooperate with the tests required for research including neuropsychological tests (cognitive ability, language ability, visual and auditory acuity can meet the requirements of the test);
  • For women of potential fertility (not yet or within 2 years of menopause), effective contraceptive measures must be used during the study period and within 6 months after the end of the study (effective contraceptive measures refer to sterilization, intrauterine hormonal devices, contraception condoms, contraceptives/dose, abstinence or partner removal of the vas deferens, etc.); male subjects should agree to use contraceptives during the study period and within 6 months after the end of the study period;
  • Able to sign the informed consent form.
  • 3. Inclusion criteria for subjects with mild to moderate AD
  • Male or female aged between 50-85 years old (including 55 and 85 years old);
  • Diagnosed as probable AD according to NIA-AA standard in 2011;
  • MMSE score≤27
  • 1≤CDR score≤2;
  • Aβ PET imaging is positive;
  • Have the ability to complete the cognitive ability test and other tests specified in the protocal;
  • The investigator judges that the subject's "caregiver" can provide accurate information and report on the patient's cognitive and functional abilities;
  • For women of potential fertility (not yet menopause or within 2 years of menopause), effective contraceptive measures must be used during the study period and within 6 months after the end of the study (effective contraceptive measures refer to sterilization, intrauterine hormonal devices, contraception condoms, contraceptives/dose, abstinence or partner removal of the vas deferens, etc.); male subjects should agree to use contraceptives during the study period and within 6 months after the end of the study period;
  • Able to sign the informed consent form.

Who cannot join

  • 1. Exclusion criteria for non-cognitively impaired subjects
  • years of education ≤6 years;
  • Severe neurological diseases, such as cerebrovascular diseases, inflammatory or infectious diseases, or any metabolic encephalopathy, neurodegenerative diseases, including Parkinson's disease history or physical or imaging manifestations;
  • History of severe craniocerebral injury, craniocerebral surgery or intracranial hematoma with permanent brain injury;
  • The results of cranial magnetic resonance imaging (MRI) also meet the following imaging findings: ①There are two or more infarcts outside the brain stem (diameter greater than 2 cm); ②Key parts such as thalamus, hippocampus, entorhinal cortex and angular gyrus Lacunar infarction; ③Fazekas score of high white matter damage ≥4;
  • Brain MRI examination showed enlarged perivascular space with subcortical diameter >3mm in short axis;
Show all 40Show fewer
  • SWI (susceptibility-weighted imaging) prompts: cerebral microbleeds ≥8 locations;
  • History of alcohol or drug abuse/dependence;
  • Contraindications of MRI examination: such as heart pacemaker or nerve stimulator or metal foreign body, high fever, etc.;
  • Invasive surgery is planned within one week after administration of the study drug;
  • Allergy to the investigational drug or any of its components and/or a history of severe allergic reaction to the drug or allergens (such as history of alcohol allergy or allergic asthma);
  • Any major disease or unstable disease state (such as unstable angina pectoris, myocardial infarction or coronary revascularization, heart failure, acute and chronic renal failure, chronic liver disease, severe lung disease, blood disease, poor blood sugar control, chronic infection in the past 2 years, received surgical treatment 7 days ago, advanced cardiac insufficiency (New York Heart Association (NYHA stage IV), etc.);
  • History of tumor within 5 years (except cervical carcinoma in situ, prostate carcinoma in situ or local skin cancer after surgery);
  • Human immunodeficiency virus (HIV), hepatitis C or Treponema pallidum antibody test positive, hepatitis B surface antigen positive (except hepatitis B carriers);
  • Received drug therapy or other treatments (such as chemotherapy) that cause large fluctuations in hematological or biochemical indicators or serious side effects within two weeks before the screening examination;
  • Receive any contrast agent or radiopharmaceutical within 48 hours before application of test drug, or will use contrast agent within 24 hours after administration of study drug;
  • Participated in clinical research of other drugs within 30 days before enrollment or within 5 half-lives of the study drug (whichever is longer), and/or used any radiopharmaceuticals before the administration of the study drug, and not more than 10 radioactive half-lives apart;
  • History of epilepsy;
  • History of electroconvulsive therapy;
  • History of delirium (e.g. after surgery);
  • Other investigators deem it inappropriate to participate in the trial.
  • 2. Exclusion criteria for subjects with MCI due to AD and mild to moderate AD
  • years of education ≤6 years;
  • Epilepsy episode occurred within the past 1 year;
  • Dementia caused by other reasons or cognitive dysfunction caused by other reasons: such as vascular dementia, Parkinson's disease dementia, Lewy body dementia, normal intracranial pressure hydrocephalus, intracranial mass, central nervous system infection (Such as HIV, syphilis, etc.), metabolic encephalopathy, etc.;
  • The results of cranial MRI also meet the following imaging findings: ①There are more than two infarcts outside the brain stem (diameter greater than 2 cm); ②Lacunar infarction in key parts such as the thalamus, hippocampus, entorhinal cortex and angular gyrus ③The Fazekas score of high white matter damage ≥ 4;
  • Brain MRI examination showed enlarged perivascular space with subcortical diameter >3mm in short axis;
  • SWI prompt: cerebral microbleeds ≥8 locations;
  • History of alcohol or drug abuse/dependence;
  • Contraindications of MRI examination: such as heart pacemaker or nerve stimulator or metal foreign body, high fever, etc.;
  • Subjects who plan to undergo surgery and/or other invasive surgery within 24 hours after the application of the trial drug;
  • Allergy to the investigational drug or any of its components and/or history of severe allergic reaction to the drug or allergens (such as history of alcohol allergy or allergic asthma);
  • Any major disease or unstable disease state (such as unstable angina pectoris, myocardial infarction or coronary revascularization, heart failure, acute and chronic renal failure, chronic liver disease, severe lung disease, blood Diabetic patients with disease, poor blood sugar control, chronic infection in the past 2 years, received surgical treatment 7 days ago, advanced cardiac insufficiency (NYHA stage IV), major depressive episode, etc.);
  • History of tumor within 5 years (except cervical carcinoma in situ, prostate carcinoma in situ or local skin cancer after surgery);
  • HIV, hepatitis C or Treponema pallidum antibody test positive, hepatitis B surface antigen positive (except hepatitis B carriers);
  • History of severe craniocerebral injury, craniocerebral surgery or intracranial hematoma with permanent brain injury;
  • Received drug therapy or other treatments (such as chemotherapy) that cause large fluctuations in hematological or biochemical indicators or serious side effects within two weeks before the screening examination;
  • Receive any contrast agent or radiopharmaceutical within 48 hours before application of test drug, or will use contrast agent within 24 hours after administration of test drug;
  • Participated in clinical research of other drugs within 30 days before enrollment or within 5 half-lives of the study drug (whichever is longer), and/or used any radiopharmaceuticals before the administration of the study drug, and not more than 10 radioactive half-lives apart;
  • Other investigators deem it inappropriate to participate in the trial.

Trial locations and contacts

1 site in 1 country.

China1 site

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, 100089

Other trials in China

About this study

Official title: An Open-label, Non-randomized, Single-center Study, Evaluating the Imaging Characteristics of XTR006 Injection in Non-cognitively Impaired Subjects, MCI Due to Alzheimer Disease (AD), and Mild to Moderate AD Subjects

This is an investigator-initiated clinical (IIT)study.The main purpose of this study was to evaluate the diagnostic efficacy of XTR006 PET qualitative reading and quantitative analysis in detecting mild cognitive impairment（MCI）due to AD and mild to moderate AD based on clinical diagnosis, and to establish XTR006 PET imaging parameters and qualitative reading and quantitative analysis methods.

Read the detailed description

XTR006 is a 18F-labeled PET tracer, for the quantification of neurofibrillary tangle (NFT) deposition in the brain. Brain NFT deposition is a pathologic finding in Alzheimer's Disease (AD), with brain NFT density shown to correlate with the severity of cognitive impairment in AD. 90 Chinese subjects (30 subjects with non-cognitive impairment, 30 subjects with MCI due to AD and 30 subjects with mild to moderate AD) who meet all of the inclusion and none of the exclusion criteriawill be enrolled in this IIT study. Subjects will receive 8-10mCi of XTR006 via IV injection. qualitative reading and quantitative analysis methods will be investigated. Safety and tolerability will be observed.

Being tested
XTR006
Keywords
Tau PET, Dosimetry, Alzheimer's disease, Chinese, XTR006
Medical subject headings
Alzheimer Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • XTR006Drug

    All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan

Study groups in NCT06151808
Study groupRoleWhat they receive
non-cognitive impairmentSham comparator30 subjects with non-cognitive impairment
Receives: Drug: XTR006
AD-derived MCIExperimental30 subjects with AD-derived MCI
Receives: Drug: XTR006
mild to moderate AD.Experimental30 subjects with mild to moderate AD.
Receives: Drug: XTR006

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To investigate the sensitivity and specificity of XTR006 PET imaging by reading

    Sensitivity and specificity of XTR006 PET images for diagnosis of MCI and AD will be measured by comparison to the standard of truth (SoT) obtained through standard of care clinical diagnosis.

    Measured: day 1

  2. To investigate the sensitivity and specificity of XTR006 PET imaging by SUVR

    Sensitivity and specificity of XTR006 PET images for diagnosis of MCI and AD will be measured by comparison to the standard of truth (SoT) obtained through standard of care clinical diagnosis.

    Measured: day 1

Secondary outcomes (5)

  1. To investigate the parameters of XTR006 PET imaging in the brain

    PET images were collected 0-130min after a single intravenous administration of XTR006, and the start time when the SUVR value of Braak brain region was stable with cerebellar gray matter as the reference area was analyzed

    Measured: 0 to 130 minutes post injection

  2. To investigate the methodology of XTR006 PET qualitative reading

    Sensitivity and specificity of different XTR006 PET qualitative reading rules for diagnosis of MCI and AD.

    Measured: day 1

  3. To investigate the consistency among XTR006 PET readers and the reproducibility of the readers themselves.

    Kappa value between XTR006 PET images readers and Kappa value of readers themselves.

    Measured: day 1

  4. To investigate the quantitative analysis methodology of XTR006 PET.

    SUVR cut off value and Sensitivity/specificity of different XTR006 PET quantitative analysis rules for diagnosis of MCI and AD.

    Measured: day 1

  5. Descripte study product-related adverse events by numbers,degree and kinds as assessed by CTCAE v5.0

    Safety Observation: Number of participants with adverse events and severe adverse events after drug injection.

    Measured: up to 7days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Nov 2023
  2. Study start1 Sep 2022
  3. Primary completion28 Nov 2023
  4. Study completion10 Jan 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
30 subjects with non-cognitive impairment, 30 subjects with MCI due to AD， 30 subjects with mild to moderate AD.
Masking
None (open label)
Enrolment
42 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06151808
Sponsor's protocol ID
STB-XTR006-IIT-01
Status last verified
May 2024
First submitted
25 Aug 2023
Last updated
3 May 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing XTR006 in people with Alzheimer Disease, run by Sinotau Pharmaceutical Group at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 29 inclusion and 40 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To investigate the sensitivity and specificity of XTR006 PET imaging by reading (time frame: day 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06151808.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in